Maraviroc

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Maraviroc, first in a new pharmacological class of antiretroviral agents known as CCR5 antagonists, has been approved by the U.S. Food and Drug Administration for the treatment of HIV-infected adult patients who are infected with only CCR5-tropic HIV-1 virus and who have HIV-1 strains resistant to multiple antiretroviral agents. Maraviroc has demonstrated in vitro activity against a wide range of CCR5 tropic clinical isolates, including those resistant to the four currently existing drug classes of antiretroviral agents. In the two pivotal phase III studies, MOTIVATE-1 and -2, maraviroc, in combination with optimized background therapy (OBT), demonstrated superior virologic and immunologic treatment outcomes than OBT alone in treatment-experienced patients infected with CCR5-tropic HIV-1. In these studies, maraviroc also demonstrated acceptable safety and tolerability profiles with adverse events and discontinuation rates in general comparable to those noted in the placebo arms.

Original languageEnglish (US)
Pages (from-to)749-758
Number of pages10
JournalDrugs of Today
Volume43
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Anti-Retroviral Agents
HIV-1
United States Food and Drug Administration
Therapeutics
Placebos
HIV
Pharmacology
Viruses
Safety
maraviroc
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Maraviroc. / Fadel, Hind; Temesgen, Zelalem.

In: Drugs of Today, Vol. 43, No. 11, 11.2007, p. 749-758.

Research output: Contribution to journalArticle

Fadel, Hind ; Temesgen, Zelalem. / Maraviroc. In: Drugs of Today. 2007 ; Vol. 43, No. 11. pp. 749-758.
@article{697de32d8e3f47fd87ef4a4ff601f8da,
title = "Maraviroc",
abstract = "Maraviroc, first in a new pharmacological class of antiretroviral agents known as CCR5 antagonists, has been approved by the U.S. Food and Drug Administration for the treatment of HIV-infected adult patients who are infected with only CCR5-tropic HIV-1 virus and who have HIV-1 strains resistant to multiple antiretroviral agents. Maraviroc has demonstrated in vitro activity against a wide range of CCR5 tropic clinical isolates, including those resistant to the four currently existing drug classes of antiretroviral agents. In the two pivotal phase III studies, MOTIVATE-1 and -2, maraviroc, in combination with optimized background therapy (OBT), demonstrated superior virologic and immunologic treatment outcomes than OBT alone in treatment-experienced patients infected with CCR5-tropic HIV-1. In these studies, maraviroc also demonstrated acceptable safety and tolerability profiles with adverse events and discontinuation rates in general comparable to those noted in the placebo arms.",
author = "Hind Fadel and Zelalem Temesgen",
year = "2007",
month = "11",
doi = "10.1358/dot.2007.43.11.1131763",
language = "English (US)",
volume = "43",
pages = "749--758",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - Maraviroc

AU - Fadel, Hind

AU - Temesgen, Zelalem

PY - 2007/11

Y1 - 2007/11

N2 - Maraviroc, first in a new pharmacological class of antiretroviral agents known as CCR5 antagonists, has been approved by the U.S. Food and Drug Administration for the treatment of HIV-infected adult patients who are infected with only CCR5-tropic HIV-1 virus and who have HIV-1 strains resistant to multiple antiretroviral agents. Maraviroc has demonstrated in vitro activity against a wide range of CCR5 tropic clinical isolates, including those resistant to the four currently existing drug classes of antiretroviral agents. In the two pivotal phase III studies, MOTIVATE-1 and -2, maraviroc, in combination with optimized background therapy (OBT), demonstrated superior virologic and immunologic treatment outcomes than OBT alone in treatment-experienced patients infected with CCR5-tropic HIV-1. In these studies, maraviroc also demonstrated acceptable safety and tolerability profiles with adverse events and discontinuation rates in general comparable to those noted in the placebo arms.

AB - Maraviroc, first in a new pharmacological class of antiretroviral agents known as CCR5 antagonists, has been approved by the U.S. Food and Drug Administration for the treatment of HIV-infected adult patients who are infected with only CCR5-tropic HIV-1 virus and who have HIV-1 strains resistant to multiple antiretroviral agents. Maraviroc has demonstrated in vitro activity against a wide range of CCR5 tropic clinical isolates, including those resistant to the four currently existing drug classes of antiretroviral agents. In the two pivotal phase III studies, MOTIVATE-1 and -2, maraviroc, in combination with optimized background therapy (OBT), demonstrated superior virologic and immunologic treatment outcomes than OBT alone in treatment-experienced patients infected with CCR5-tropic HIV-1. In these studies, maraviroc also demonstrated acceptable safety and tolerability profiles with adverse events and discontinuation rates in general comparable to those noted in the placebo arms.

UR - http://www.scopus.com/inward/record.url?scp=38349019887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349019887&partnerID=8YFLogxK

U2 - 10.1358/dot.2007.43.11.1131763

DO - 10.1358/dot.2007.43.11.1131763

M3 - Article

C2 - 18174962

AN - SCOPUS:38349019887

VL - 43

SP - 749

EP - 758

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 11

ER -